Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a specific type of mixed blood cancer called MPAL (Mixed Phenotype Acute Leukemia), confirmed by laboratory testing according to 2022 medical guidelines.
• People who have previously had a stem cell transplant from a donor may still be considered, provided it was at least 4 weeks ago, there is no significant transplant-related immune reaction (graft-versus-host disease above a mild level), and immune-suppressing medications have been stopped for at least 1 week (or at least 4 weeks for a specific type called calcineurin inhibitors).
• People who have leukemia affecting the brain or spinal fluid may still be considered, provided their condition is stable, symptoms have not worsened in the past 4 weeks, and a spinal fluid test taken within the past 2 weeks shows no cancer cells detected by flow cytometry.
• People who are willing and able to sign a consent form agreeing to take part in the study.
• People who are able to attend the required clinic or hospital visits and follow the study requirements.
• People who have abnormal blood test results related to their blood cancer at the time of joining — this is expected and does not prevent participation.

For Cohort A specifically (newly diagnosed patients not suitable for intensive chemotherapy):

• People aged 75 or older, OR people who have at least one of the following health conditions that make intensive chemotherapy unsuitable: a history of heart failure requiring treatment or a heart pumping function of 50% or less in the past 12 months; a history of stable chest pain (angina); lung function test results below certain thresholds in the past 12 months; a physical performance rating of 3 or 4 on a standard medical scale; or a combined health burden score of 3 or higher on the Charlson Comorbidity Index (confirm with trial site).

For Cohort B specifically (patients in remission but with detectable remaining cancer):

• People with CD19+ MPAL (a specific type identified by a marker called CD19) who are in remission after at least one round of treatment, but where sensitive testing still detects a small amount of remaining cancer at a level of 0.1% or above.
• People with a physical performance rating of 2 or lower on a standard medical scale.
• People whose liver and kidney function tests fall within the ranges required by the trial (confirm specific values with trial site).

For Cohort C specifically (patients whose cancer has returned or not responded to treatment):

• People with CD19+ MPAL that has come back or has not responded to previous treatment.
• People who have finished previous chemotherapy at least a set number of days before starting this trial (based on the specific drugs used), and whose side effects from prior chemotherapy have reduced to a mild level or resolved.
• People with a physical performance rating of 2 or lower on a standard medical scale.
• People whose liver and kidney function tests fall within the ranges required by the trial (confirm specific values with trial site).

Who may not be able to join:

• People who are currently receiving another experimental treatment, or who are receiving chemotherapy, radiation therapy, or immunotherapy for their cancer at the same time — although corticosteroids and a drug called hydroxyurea are exceptions and do not disqualify participation.
• People who have an active infection that is not being treated or is not under control — though people with an infection that is being actively treated and is responding to antimicrobial medication may still be considered.

Important: Always verify eligibility with the trial site directly before applying.